Mulugeta Asefa Gutu1, Alemayehu Bekele2, Yimer Seid3, Abyot Bekele Woyessa1. 1. Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 2. Ethiopian Public Health Association, Addis Ababa, Ethiopia. 3. Addis Ababa University School of Public Health, Addis Ababa, Ethiopia.
Abstract
INTRODUCTION: measles is the leading vaccine preventable childhood disease designated for elimination by WHO. More than 20 million people are affected by measles each year, particularly in Africa and Asia. With annual outbreaks reported from Ethiopia´s Oromia region. We analyzed measles containing vaccine coverage (MCV), measles cases and measles deaths over a 10-year period (2007-2016). METHODS: we reviewed Oromia measles surveillance data and first-dose measles containing vaccine (MCV1) administrative coverage. Descriptive statistics and multivariable logistic regression were performed to assess variables associated with measles death. Additional spatial mapping was performed to visually display key areas of measles case distribution in Oromia. RESULTS: a total of 26,908 measles suspect cases were identified, of which 18,223 (68%) were confirmed. A median age of 6 years (IQ range 0.5-71 years) and 288 deaths were observed. Among the total cases, 29% were unvaccinated and 46% had unknown vaccination status. The highest IR was seen in Guji zone (IR=190/100,000 population) among 1-4 years, with a majority from rural areas. Risk factors associated with death include age <5 years (AOR=1.82, CI: 1.42-2.33), unvaccinated status (AOR=1.44, CI: 1.06-1.95) and inpatient treatment (AOR=2.12, CI: 1.58-2.85). Of 8,732 measles IgM negative/indeterminate specimens, 10.5% tested positive for rubella specific IgM. CONCLUSION: outbreaks of measles are an ongoing public health concern in the Oromia region. Children aged 1-15 years remain at high risk for contracting measles in the region. We recommend strengthening routine immunization to reach all children, especially in rural areas and that the measles-rubella (MR) vaccine be considered. Copyright: Mulugeta Asefa Gutu et al.
INTRODUCTION: measles is the leading vaccine preventable childhood disease designated for elimination by WHO. More than 20 million people are affected by measles each year, particularly in Africa and Asia. With annual outbreaks reported from Ethiopia´s Oromia region. We analyzed measles containing vaccine coverage (MCV), measles cases and measles deaths over a 10-year period (2007-2016). METHODS: we reviewed Oromia measles surveillance data and first-dose measles containing vaccine (MCV1) administrative coverage. Descriptive statistics and multivariable logistic regression were performed to assess variables associated with measles death. Additional spatial mapping was performed to visually display key areas of measles case distribution in Oromia. RESULTS: a total of 26,908 measles suspect cases were identified, of which 18,223 (68%) were confirmed. A median age of 6 years (IQ range 0.5-71 years) and 288 deaths were observed. Among the total cases, 29% were unvaccinated and 46% had unknown vaccination status. The highest IR was seen in Guji zone (IR=190/100,000 population) among 1-4 years, with a majority from rural areas. Risk factors associated with death include age <5 years (AOR=1.82, CI: 1.42-2.33), unvaccinated status (AOR=1.44, CI: 1.06-1.95) and inpatient treatment (AOR=2.12, CI: 1.58-2.85). Of 8,732 measles IgM negative/indeterminate specimens, 10.5% tested positive for rubella specific IgM. CONCLUSION: outbreaks of measles are an ongoing public health concern in the Oromia region. Children aged 1-15 years remain at high risk for contracting measles in the region. We recommend strengthening routine immunization to reach all children, especially in rural areas and that the measles-rubella (MR) vaccine be considered. Copyright: Mulugeta Asefa Gutu et al.
Authors: Robin Nandy; Thomas Handzel; Maman Zaneidou; José Biey; Rene Z Coddy; Robert Perry; Peter Strebel; Lisa Cairns Journal: Clin Infect Dis Date: 2005-12-19 Impact factor: 9.079
Authors: Lara J Wolfson; Rebecca F Grais; Francisco J Luquero; Maureen E Birmingham; Peter M Strebel Journal: Int J Epidemiol Date: 2009-02 Impact factor: 7.196
Authors: Genevie M Ntshoe; Johanna M McAnerney; Brett N Archer; Sheilagh B Smit; Bernice N Harris; Stefano Tempia; Mirriam Mashele; Beverley Singh; Juno Thomas; Ayanda Cengimbo; Lucille H Blumberg; Adrian Puren; Jocelyn Moyes; Johann van den Heever; Barry D Schoub; Cheryl Cohen Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: R F Grais; C Dubray; S Gerstl; J P Guthmann; A Djibo; K D Nargaye; J Coker; K P Alberti; A Cochet; C Ihekweazu; N Nathan; L Payne; K Porten; D Sauvageot; B Schimmer; F Fermon; M E Burny; B S Hersh; P J Guerin Journal: PLoS Med Date: 2007-01 Impact factor: 11.069
Authors: Alya Dabbagh; Rebecca L Laws; Claudia Steulet; Laure Dumolard; Mick N Mulders; Katrina Kretsinger; James P Alexander; Paul A Rota; James L Goodson Journal: MMWR Morb Mortal Wkly Rep Date: 2018-11-30 Impact factor: 17.586
Authors: Alya Dabbagh; Minal K Patel; Laure Dumolard; Marta Gacic-Dobo; Mick N Mulders; Jean-Marie Okwo-Bele; Katrina Kretsinger; Mark J Papania; Paul A Rota; James L Goodson Journal: MMWR Morb Mortal Wkly Rep Date: 2017-10-27 Impact factor: 17.586